Beta Drugs Limited has filed a Monitoring Agency Report for the half year ending March 31, 2025, detailing an equity and CCD preferential issue that raised a total of ₹117.01 Crore, noting a received amount of ₹0.01 Crore for equity shares due to non-allotment issues.